- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00633295
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome. The median survival for patients with unresectable or metastatic GIST is approximately 20 months, and for patients with local recurrence it is 9 to 12 months. Responses to chemotherapy have been at best 5%. The introduction of imatinib has dramatically changed the prognosis of these patients yielding response rates between 41% and 71% and an overall clinical benefit (tumor responses plus stable disease) ranging between 73% and 90%.
However, resistance to imatinib may develop and represents a further clinical challenge. Sunitinib has recently been approved by the FDA for patients whose disease has progressed or who are intolerant to imatinib therapy. Patients with tumor progressing on sunitinib or another 2nd line agent have limited therapeutic alternatives. Reinstitution of imatinib, if possible, is considered an acceptable option for these patients because it may slow the rate of disease progression even in the setting of prior imatinib failure; however a more optimal 3rd line treatment is needed. AMN107 is a novel aminopyrimidine, available as an oral formulation that is ATP -competitive inhibitor of BCR-ABL,more potent than Imatinib. It inhibits proliferation and autophosphorylation of 32 out of 33 BCR-ABL point mutations. In addition AMN107 also inhibits PDGFRα,PDGFRβ, and KIT. Preliminary data from an ongoing Phase I study in imatinib-resistant GIST patients (CAMN107A2103) indicate that AMN107 alone (400 mg BID) and in combination with imatinib (imatinib 400 mg BID plus AMN107 200 mg QD and 400 mg QD) is well tolerated in this pre-treated patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel
- Novartis Investigative Site
-
Tel Aviv, Israel
- Novartis Investigative Site
-
Tel Hashomer, Israel
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age ≥ 18 years at Visit 1
- Radiological confirmation of disease progression (CT scan PET-CT, or MRI) during imatinib therapy, on 600- 800 mg per day for at least 6 weeks.
- Radiological confirmation of disease progression (CT scan or MRI and PET-CT) during 2nd line TK inhibitor therapy.
- Patients who were intolerant to Imatinib or second line TK inhibitor (like :sunitinib). Intolerance (at any dose and/or duration), is defined as patients who did not progress on imatinib or sunitinib and have discontinued imatinib and or sunitinib therapy due to any ≥ Grade 3 adverse events that persist in spite of optimal supportive care. Patients with Grade 2 adverse events related to imatinib or sunitinib therapy, in spite of optimal supportive care measures, that persist for ≥ one month or that recurs for more than 3 times whether the dose is reduced or discontinued will also qualify patients as intolerant
Exclusion criteria:
- Prior treatment with nilotinib
- Treatment with any investigational drug ≤ 4 weeks prior to Visit 1 with the exception of imatinib and sunitinib therapy .
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: nilotinib
|
The dose of nilotinib will be 400 mg bid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAMN107DIL02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Stromal Tumors (GIST)
-
Centre Leon BerardRecruitingC-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)France
-
Centre Leon BerardRecruitingMetastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)France
-
Centre Leon BerardGustave Roussy, Cancer Campus, Grand ParisCompletedSarcoma | Gastro-intestinal Stromal Tumors (GIST)France
-
Blueprint Medicines CorporationCompletedGastrointestinal Stromal Tumors (GIST) | Other Relapsed or Refractory Solid TumorsUnited States, United Kingdom, France, Korea, Republic of, Belgium, Germany, Italy, Netherlands, Poland, Spain
-
National University Hospital, SingaporeUnknownAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With ImatinibSingapore
-
Novartis PharmaceuticalsCompleted3rd Line GISTFrance, United Kingdom, Belgium, Canada, Spain, Netherlands, Japan, United States
-
Novartis PharmaceuticalsCompleted3rd Line GISTItaly, Belgium, Spain, Netherlands, Germany, United Kingdom, France, United States
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingGastrointestinal Stromal Tumor (GIST)Taiwan
-
Kristen GanjooGlaxoSmithKlineTerminatedGastrointestinal Stromal Tumor (GIST)United States
-
Instituto Ecuatoriano de Enfermedades DigestivasRecruitingGastrointestinal Stromal Tumor (GIST)Ecuador
Clinical Trials on AMN107- NILOTINIB
-
Novartis PharmaceuticalsCompleted
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's HospitalCompletedMelanoma | Acral Melanoma | Mucosal Lentiginous MelanomaUnited States
-
Novartis PharmaceuticalsCompletedChronic Myeloid LeukemiaGermany
-
Novartis PharmaceuticalsCompletedPhiladelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myelogenous, ChronicUnited States
-
Gruppo Italiano Trapianto di Midollo OsseoCompletedChronic Graft Versus Host DiseaseIsrael, Italy
-
Weill Medical College of Cornell UniversityNovartis PharmaceuticalsCompletedChronic Myeloid LeukemiaUnited States
-
Novartis PharmaceuticalsCompletedChronic Myelogenous LeukemiaTurkey
-
Stanford UniversityNovartisCompletedLymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant FailureUnited States, Canada
-
Rony SchaffelTerminatedAcute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma